查詢結果分析
來源資料
相關文獻
- The Effects of Ciprofloxacin on Chest Radiographic Regression in Patients with Drug Intolerance or Resistant Tuberculosis
- Short-Course Chemotherapy for Isoniazid-Resistant Pulmonary Tuberculosis
- Fluoroquinolones經驗療法對肺結核之影響
- 動機式會談於一位無意圖服藥多重抗藥性肺結核病人
- 結核菌藥物感受性試驗判讀標準的省思
- 肺結核菌及其抗藥性診斷之現況、困境與發展
- 使用Prothionamide於多重抗藥性肺結核病患造成甲狀腺功能低下之案例報告
- Clinical Experience with Multidrug--Resistant Tuberculosis in a TB Referral Hospital
- Clinical Characteristics of Pulmonary Tuberculosis Patients from a Southern Taiwan Hospital--Based Survey
- 廣泛抗藥性結核菌--結核病治療新威脅
頁籤選單縮合
題 名 | The Effects of Ciprofloxacin on Chest Radiographic Regression in Patients with Drug Intolerance or Resistant Tuberculosis=Ciprofloxacin影響藥物耐受不良或抗藥性結核病患的胸部病兆 |
---|---|
作 者 | 楊朝凱; 林鴻銓; 李岡遠; 林恕民; 余志騰; 郭漢彬; | 書刊名 | 長庚醫學 |
卷 期 | 27:4 2004.04[民93.04] |
頁 次 | 頁292-299 |
分類號 | 415.2773 |
關鍵詞 | 肺結核; 藥物耐受不良; 抗藥性; Ciprofloxacin; Pulmonary tuberculosis; Drug intolerance; Drug resistance; |
語 文 | 英文(English) |
中文摘要 | 背景:此研究是為了探討當肺結核病患對於傳統抗結核藥物耐受不良或抗藥菌種出現時,ciprofloxacin作為第二線藥物的臨床療效。 方法:20位有藥物耐受不良或抗藥菌種的肺結核病患歸入ciprofloxacin治療組,使用ciprofloxacin來合併或取代傳統抗結核藥物。另外有32位病患在相同情況下,仍維持原先傳統抗結核藥物,則歸入非ciprofloxacin治療組。胸部攝影以評分系統作分級。胸部病兆消散速度在兩群病患中亦同時作比較。 結果:資料顯示在具抗藥性結核病患ciprofloxacin治療組比非ciprofloxacin治療組胸部病兆消散較快(p<0.01)。在ciprofloxacin治療組的藥物耐受不良病患,治療前和治療後的胸部攝影評分為3.1±0.2 以及 2.2±0.3(p<0.001)。而對於非ciprofloxacin治療組的藥物耐受不良病患,治療前的胸部攝影評分為3.7±0.4,治療後為3.0±0.4(p<0.05)。在ciprofloxacin治療組的具抗藥緎結核病患,治療前和治療後的胸部攝影評分為4.3±0.4以及3.4±0.5(p<0.05)。而對於非ciprofloxacin治療組的藥物耐受不良病患,治療前的胸部攝影平分為3.7±0.3,治療後為3.2±0.3(無統計學之差異)。很顯然地在藥物耐受不良病患中,ciprofloxacin使用在兩組病患的胸部病兆改善具相同臨床療效。除此之外在具抗藥性結核病患中,ciprofloxacin治療組比非ciprofloxacin治療組在治療過過中有較快胸部病兆消散以及治療後有較好的胸部病兆改善。 結論:對於肺結核病患無法使用傳統第一線抗結核藥物,如藥物耐受不良或具抗藥緎結核時,在此我們提供一個第二線藥物的良好選擇ciprofloxacin,來治療這類病患。 |
英文摘要 | Background: The aim of this study was to identify the clinical efficacy of ciprofloxacin as a second-line anti-tuberculosis agent in pulmonary tuberculosis patients with drug intolerance or resistance. Methods: There were 20 patients with drug related adverse effects or drug resistance enrolled in the ciprofloxacin treatment group(CG). There were also 32 patients enrollment in the non-ciprofloxacin treatment group(NCG) that maintained conventional drug regimens or the addition of other drugs like streptomycin. The radiographic presentation was evaluated using score grading. The speed and outcome of regression in the chest radiographic presentations were also evaluated. Results: Data showed the CG had significantly more rapid regression than the NCG in drug-resistant patients (p<0.01). for the adversely effected patients in the CG, the mean scores of pre- and post-treatment were 3.1±0.2 and 2.2±0.3(p<0.001), respectively. For the adversely effected patients in the NCG, the mean score of pre-treatment was 3.7±0.4 and post-treatment mean score was 3.0±0.4(p<0.05). For the drug-resistant patients in the CG, the mean scores of pre- and post-treatment were 4.3±0.4 and 3.4±0.5(p<0.05), respectively. For the drug-resistant patients in the NCG, the mean score of pre-treatment was 3.7±0.3 and post-treatment mean score was 3.2±0.3(no significant difference). Obviously, the CG had the same effects compared with the NCG in adverse-effect group. On the other hand, the CG and the tendency of more rapid radiographic regression and better radiographic outcomes than the NCG in drug-resistant patients. Conclusions: Ciprofloxacin provides a better option for second-line drug treatment for pulmonary tuberculosis when patients cannot use conventional anti-tuberculosis agents. |
本系統中英文摘要資訊取自各篇刊載內容。